- Investigator
- Kethandapatti Balaji
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
Treats Adults
Kethandapatti Balaji, MBBS (MD), FRCS, MRCS, LRCP
Urologist
Rated
4.8
out of 5 stars
(904) 383-1016
Request appointment online
Research at a glance
Top areas of exploration
- Prostatic Neoplasms , 20 publications
- Protein Kinase C , 5 publications
- Prostate , 5 publications
- Postoperative Complications , 5 publications
Research activity
Active clinical trials
- Investigator
- Kethandapatti Balaji
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All
- Investigator
- Kethandapatti Balaji
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
My publications
Filter publications
53 publications
2026
Lutetium-177–PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies
Urologic Oncology: Seminars and Original Investigations
Publisher's site2026
Network meta-analysis of immune checkpoint inhibitors in BCG-naïve, high-risk non-muscle-invasive bladder cancer
Urologic Oncology: Seminars and Original Investigations
Publisher's site2026
An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations
Publisher's site2026
Protein Kinase D1 Translocates PARP1 to the Membrane and Is Associated With Increased Sensitivity to Cell Viability Inhibition by PARP1 Inhibitor Olaparib.
The Prostate
PubMed • Publisher's site2026
Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
PubMed • Publisher's site